Drug Profile

ALTO 101

Alternative Names: ALTO-101T TDS; ALTO-101; ALTO-101T

Latest Information Update: 18 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alto Neuroscience
Class Antipsychotics; Small molecules
Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Schizophrenia
Discontinued Neurodegenerative disorders; Psychiatric disorders

Most Recent Events

13 Feb 2026 Alto Neuroscience completes enrolment in the phase-II trial in Schizophrenia (Transdermal) in USA (NCT06502964)
20 Oct 2025 Pharmacokinetics data from a phase-II trial in Schizophrenia released by Alto Neuroscience
03 Oct 2025 ALTO 101 receives Fast Track designation for Schizophrenia [Transdermal] in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com